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Abstract
Ovarian cancer is the fourth most common cause of cancer deaths among women, and chronic alcoholism may exert co-
carcinogenic effects. Because melatonin (mel) has oncostatic properties, we aimed to investigate and characterize the
chemical induction of ovarian tumors in a model of ethanol-preferring rats and to verify the influence of mel treatment on
the overall features of these tumors. After rats were selected to receive ethanol (EtOH), they were surgically injected with
100 mg of 7,12-dimethyl-benz[a]anthracene (DMBA) plus sesame oil directly under the left ovarian bursa. At 260 days old, half
of the animals received i.p. injections of 200 mg mel/100 g b.w. for 60 days. Four experimental groups were established:
Group C, rats bearing ovarian carcinomas (OC); Group C+EtOH, rats voluntarily consuming 10% (v/v) EtOH and bearing OC;
Group C+M, rats bearing OC and receiving mel; and Group C+EtOH+M, rats with OC consuming EtOH and receiving mel.
Estrous cycle and nutritional parameters were evaluated, and anatomopathological analyses of the ovarian tumors were
conducted. The incidence of ovarian tumors was higher in EtOH drinking animals 120 days post-DMBA administration, and
mel efficiently reduced the prevalence of some aggressive tumors. Although mel promoted high EtOH consumption, it was
effective in synchronizing the estrous cycle and reducing ovarian tumor mass by 20%. While rats in the C group displayed
cysts containing serous fluid, C+EtOH rats showed solid tumor masses. After mel treatment, the ovaries of these rats
presented as soft and mobile tissues. EtOH consumption increased the incidence of serous papillary carcinomas and
sarcomas but not clear cell carcinomas. In contrast, mel reduced the incidence of sarcomas, endometrioid carcinomas and
cystic teratomas. Combination of DMBA with EtOH intake potentiated the incidence of OC with malignant histologic
subtypes. We concluded that mel reduces ovarian masses and the incidence of adenocarcinomas in ethanol-deprived rats.
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Introduction
OC is the most lethal of all of the gynecological malignances [1].
The high incidence of OC has been attributed to primordial
factors that are associated with ovarian senescence, such as oocyte
depletion, low levels of steroid production, and increased levels of
circulating gonadotropins [2]. OC has been presumed to arise
from precursor lesions involving the ovarian surface epithelium
(OSE) or ovarian epithelial inclusion cysts, which exhibit
morphological features of the reproductive tract epithelium (or
Mullerian aspects). Mullerian inclusion cysts may develop from the
tubal epithelia by exfoliation or tubal-ovarian adhesions, during
ovulation repair, or may even develop from endometrial cells via
endometriosis [3–5]. Furthermore, several events associated with
ovulation are hypothesized to be linked to OC initiation and
progression, including proliferation of the OSE to repair
ovulation-induced wounds on the ovarian surface [6], which
may result in DNA damage; elevation of gonadotropin levels,
stimulating the growth of the OSE [7]; and ovulation-induced
inflammation, leading to the generation of reactive oxygen species
(ROS) [8]. Approximately 90% of OCs are believed to arise from
the OSE, while the remainder of ovarian neoplasms seem to be
closely split between stromal and germ cell origins [9,10]. The lack
of an adequate screening method to detect the early stages of the
disease and its progression to chemoresistance has prevented
appreciable improvements in the survival rate of patients suffering
from OC.
Unfortunately, a paucity of OSE tumor animal models exist that
can be extrapolated to tumors occurring in women. 7,12-
dimethylbenz[a]anthracene (DMBA) is a well-known polycyclic
aromatic carcinogen that is capable of inducing the initiation,
promotion and progression of tumors [11]. After an optimal
period of ovarian instillation, the observed neoplasms develop into
massive tumors and occasionally evolve to intraperitoneal nodules
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that are accompanied by bloody ascites [12,13]. Importantly, the
histologic types of experimental ovarian tumors may vary based on
the animal strain used, the age of the animals, and the use of the
carcinogen (the amount, route of administration, and method of
induction). To date, the effective detection and specific treatment
of OC remains a significant clinical challenge.
Evidence that suggests a plausible biological relationship exists,
revealing that higher doses of alcohol consumption cause
anovulation, and hence, protection against ovarian carcinogenesis
[14]. Conversely, an American hospital-based study reported a
direct association between alcohol drinking and OC risk, while
other studies detected no relationship [15–17]. Despite these
conflicting results, an animal model of OC in which the hormone
profile and ovarian metabolism were severely disrupted by ethanol
consumption would represent a good choice for investigating the
potential of a carcinogen together with a risk factor (e.g., alcohol
intake). Our ethanol-preferring rat strain, UChB, was derived
from the original Wistar rat, and has been selectively bred at the
University of Chile for decades [18]. These animals are considered
to be a special model that can be used to understand alcoholism-
linked characteristics, such as those observed in human diseases. A
model possessing the histologic patterns appropriate to those found
in human ovarian tumors is needed to evaluate new chemopre-
ventive compounds.
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine
that is produced by the pineal gland and secreted in a circadian
manner overnight [19]. Melatonin has indisputably been impli-
cated as a therapeutic agent in several cases, including the
treatment of reproductive cancers [20,21]. Due to its functional
versatility, melatonin has been recognized as having antioxidant,
oncostatic and immunomodulatory properties [22]. Some cyto-
kines (IL-2, -4 and -12) and factors (TNF-alpha and INF-gamma)
displaying immunotherapeutic potential have been associated with
melatonin and are under investigation for use as adjuvant
therapies for cancer [23,24]. Furthermore, multiple reports have
indicated that melatonin prevents the initiation, promotion and
progression of tumors [22,23]. The efficacy of melatonin in
limiting the proliferation of tumor cells has also been demonstrated
to be dependent upon the timing of administration, with the
optimal timing being the end of the most suitable light phase [25].
The oncostatic effects of melatonin have also been shown to be
more pronounced in hormone-dependent tumors (e.g., breast and
ovarian cancers) [20]. In an effort to better understand this issue,
the present study was designed to characterize the chemical
induction of ovarian tumors in a model of ethanol-preferring rats,
and to investigate the role of melatonin in the overall features of
ovarian tumors.
Materials and Methods
Animals and Experimental Design
Eighty adult (60 day old) UChB (a non-isogenic model of
ethanol-preferring rats that was developed by selective breeding to
study the effects of chronic ethanol consumption) female rats,
weighing 6200–230 g, were obtained from the Department of
Anatomy, Bioscience Institute/Campus of Botucatu, UNESP–
Univ Estadual Paulista. The rats were individually housed in
polypropylene cages containing laboratory-grade pine shavings as
bedding and maintained under controlled room temperature
(2361uC) and lighting conditions (12 h light and 12 dark
photoperiods, with the lights switched on at 6 a.m.). Filtered tap
water and standard rodent chow (3074 SIF, Purina Ltda.,
Campinas, SP, Brazil) containing (by weight) 19.90% protein,
30.03% carbohydrate, 3.80% fat, 13.36% fiber, and 3.00 kcal/g
of metabolizable energy were provided ad libitum. All animals were
divided into two arms (n = 40/group): an EtOH group, in which
the rats had access to a 10% (v/v) ethanol solution ad libitum (free
choice of water or ethanol), and a control group, which was
composed of ethanol-naı¨ve rats without access to ethanol. When
the UChB EtOH rats had reached 65 days of age, they were given
a choice between two bottles containing either water (1) or a 10%
(v/v) ethanol solution (2) ad libitum over a period of 15 days. After
this period, animals displaying ethanol consumption higher than
2.0 g of EtOH/kg/day (ranging from 4 to 5 g of EtOH/kg/day)
were selected according to the procedure outlined by Mardones
and Segovia-Riquelme [18]. In the present study, the preference
ratio associated with ethanol-seeking behavior was approximately
65%.
At 80 days of age, all of the animals were chemically induced via
injection of DMBA (Sigma Chemical Co, St Louis, MO) directly
into the left ovarian bursa (please see item 2.3 of the Methods
section). Over the subsequent 180 days of the experimental period,
the rats were followed, and tumor development was observed
using ultrasonography. Ovarian size (volume and diameter) was
used as a reference parameter during tumor development.
The animals designated to receive mel (n = 40) were adminis-
tered i.p. doses of 200 mg/100 g of BW during the nocturnal
period over the course of 60 consecutive days (please see item 2.4
of the Methods section and Fig. 1A).
For this proposal, the rats were finally divided into four groups:
Group C, composed of DMBA-induced animals that did not
consume ethanol; Group C+EtOH, composed of DMBA-induced
animals that consumed 10% (v/v) ethanol during ovarian tumor
development (OTD); Group C+M, composed of DMBA-induced
animals that received melatonin as therapy; and Group
C+EtOH+M, composed of DMBA-induced animals that con-
sumed 10% (v/v) ethanol during OTD and received melatonin as
therapy. After the experimental period, the females (whether
cycling or not) were anesthetized and euthanized by decapitation
(during the early morning at 4 a.m.) prior to further sample
collection.
Ethics Statement
To minimize pain, suffering or distress during experimentation,
all of the animals were anesthetized with ketamine (50 mg/kg) and
xylazine (10 mg/kg) prior to decapitation so that they were
rendered unconscious. At 320 days of age, euthanasia was
performed in accordance with the Canadian Council on Animal
Experimentation. The present experimental protocol was previ-
ously accepted by the Ethical Committee of the Institute of
Bioscience/UNESP (CEEA – Comiteˆ de E´tica em Experimenta-
c¸a˜o Animal), Campus of Botucatu, SP, Brazil (Permit Number:
382).
Ovarian Tumor Induction Procedure
After being selected to consume ethanol, all of the animals
(n = 80) were anesthetized with 10% ketamine (60 mg/kg, i.p.) and
2% xylazine (5 mg/kg, i.p.) during the estrous stage. After the
administration of anesthesia (1.2 mL/100 g of BW), the left flank
region of the skin was cleaned with iodine and 70% ethanol. A 2 -
cm incision was made through the skin and abdominal wall, and
the ovaries were accessed by grasping the fat pad near the left
kidney. After exteriorization, the left ovary was injected with a
single dose of 100 mg of DMBA dissolved in 10 mL of sesame oil,
which was used as the vehicle [26], directly under the ovarian
bursa, and returned intact to the body cavity. The muscle layer
and skin was closed using a 3-0 silk suture (Ethicon Inc., Me´xico,
MX). Sham surgery was conducted on the right ovary using the
Ovarian Cancer & Ethanol: Benefits of Melatonin
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vehicle only. Antibiotic (105 units of benzylpenicillin potassium)
was administered i.p. for the prophylactic treatment of infections
before the abdominal wall was closed.
Mel Administration Procedure
Mel (M-5250, Sigma-Aldrich Chemical Co., St. Louis, MO,
USA) was dissolved in 0.04 mL of 95% ethanol and diluted in
0.3 mL of 0.9% NaCl (vehicle) at a steady-state concentration of
0.3 mg/mL. The mixture was then injected i.p. in a total volume
of 3.4 mL/kg of BW. All of the treated and untreated animals
were injected with a vehicle solution. For the melatonin
treatments, i.p. injections at doses of 200 mg/100 g of BW were
administered daily for 60 days [27] in the evening (between 18:30–
19:00 hours, at ZT 13, as shown in Fig. 1B).
Evaluation of Estrous Cycle and Nutritional Parameters
During the post-induction period, estrous cycles were monitored
daily (at 9 a.m.) using a vaginal swab technique [28]. Fresh
samples were transferred to clean slides and examined under an
optical microscope. In addition, body weight gains, food
consumption, and water/ethanol intake were measured every
day at 9 a.m. for a period of each five days. After the melatonin
treatment period, all of the rats were monitored by vaginal
swabbing in a dark room using red dim illumination for
subsequent euthanasia (anesthesia followed by decapitation)
during the early morning at 4 a.m. (or Zeitgeber Time (ZT) 22,
corresponding to the environmental circadian time, as shown in
Fig. 1B).
Determination of Plasma Mel Concentrations
After blood collection (4 a.m.), mel was extracted from the
plasma (n = 10 samples/group) using HPLC grade methanol and
was then separated on columns (Sep-Pak Vac C-18, reverse phase,
12.5 nm) (Water Corporation, Milford, Massachusetts, USA).
Thereafter, 50 mL of reconstituted samples were assayed using a
Coat-a-count Melatonin ELISA Kit and measured at 405 nm.
The intra-assay coefficient of variation was 4%. All of the samples
were assayed in duplicate at the same time to avoid inter-assay
variability. All of the reagents and microtiter plates were provided
by IBL (IBL International, Hamburg, Germany). The concentra-
tions of melatonin are reported as pg/mL.
Ovarian Histology Analyses
After euthanasia, all of the animals were necropsied and
examined for abnormalities. Pathologically altered organs, female
reproductive tracts, and organs/tissues related to body metabolism
(liver, kidneys, pancreas, intestines, lymph nodes, and spleen) were
removed during necropsy. In rats with evident ovarian tumors,
specimens were also excised and frozen in liquid nitrogen, followed
by storage at 280uC. For the histological analyses, the ovaries
were fixed in 10% (v/v) buffered formalin (for 24 h), transferred to
70% ethanol, dehydrated, and paraffin embedded. Sections that
were 5-mm thick were generated, and every 20th section was
stained with hematoxylin and eosin (H&E). Histopathological
analyses were conducted by a pathologist with expertise in animal
malignancies. The ovarian tumors were subtyped according to the
histological aspects of the neoplasms.
Statistical Analysis
The values are presented as the means 6 standard deviation
(SD). The data analyses were performed using two-way ANOVA
(analysis of variance) for two independent factors (ethanol
consumption and mel treatment). Significant results were subject-
ed to post-hoc testing using Tukey’s test, and statistical significance
was set at p,0.05. GraphPad Instat Version 4 statistical software and
Sigma Plot Version 11.0 graphing software were used in this study.
Results
Nutritional Parameter and Estrous Cycle Examinations
During the experimental period, all of the animals were
monitored and handled based on the same criteria. The amount
of food intake and energy intake (derived from the feed and
ethanol) did not differ between the experimental groups (p.0.05).
However, the animals in Group C, independent of mel treatment,
consumed more water than those in Group C+EtOH, regardless
of treatment. Ethanol consumption was unaltered after ovarian
tumor induction. When mel was administered, the amount of
ethanol consumed increased after the first week through the end of
the treatment period (34% increase in Group C+EtOH+M as
compared to Group C+EtOH, as shown in Table 1).
After tumor induction, the estrous cycles of rats in both Groups
C and C+EtOH were longer (25% and 30.3% increase compared
to Groups C+M and C+EtOH+M, respectively), and displayed
transitional phase irregularities, particularly prolongation in the
diestrus phase (50% of the analyzed period). Notably, mel was
effective in reducing both the duration of the estrous phase and the
extension of the diestrus phase. The disturbances in the estrous
phase did not differ statistically between the groups (Table 2).
Figure 1. Detailed schedule of the experimental design. (A) Chronological scheme of ethanol intake, ovarian tumor induction and mel
treatment (days). (B) Schematic protocol that was used for daily melatonin administration based on Zeitgeber Time (ZT), corresponding to
environmental circadian time. ZT 13: Melatonin administration period. ZT 22: Period of euthanasia.
doi:10.1371/journal.pone.0081676.g001
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Body and Reproductive Organs Weights
No differences in the final body weights or body weight gains
(p.0.05) were observed during the experimental period. The
absolute and relative weights and sizes of the left ovaries were
significantly higher in the animals in Groups C and C+EtOH, and
treatment with mel reduced these ovarian masses by approxi-
mately 20% (Table 3). Only animals that had undergone left
tumor induction and consumed ethanol displayed decreased right
ovarian weights, and mel therapy promoted an additive effect in
the presence of ethanol, restoring these weights to normal. Finally,
the oviduct and uterine weights remained unchanged during the
treatments (Table 3).
Incidence of Ovarian Tumors and Plasma Melatonin
Levels
The incidence of DMBA-induced ovarian tumors (the percent-
age of animals in each group that developed tumors) was higher in
animals that consumed ethanol (Fig. 2A). Thus, at 80 days post-
induction (DPI), the incidence was 22% in Group C+EtOH and
17% in Group C. At 100 DPI, the rate was 25% in Group
C+EtOH and 24% in Group C. At 120 DPI, the rate was 42% in
Group C+EtOH and 32% in Group C. At 140 DPI, the rate was
44% in Group C+EtOH and 36% in Group C. At 160 DPI, the
rate was 64% in Group C+EtOH and 47% in Group C. At 180
DPI, the rate was 74% in Group C+EtOH and 60% in Group C
(Fig. 2A). After 30 and 60 days of mel administration, both Groups
C+M and C+EtOH+M displayed significant increases in plasma
mel concentrations compared to Groups C and C+EtOH. After 60
days of treatment, only the rats in the C+M group showed
elevations in mel levels compared to 30 days of treatment (Fig. 2B).
Anatomopathological Ovarian Tumor Analyses
After sequential tumor development, the abdominal-pelvic
cavity was opened to assess ovarian tumors. The left ovaries of
rats from the C+EtOH group displayed evident solid masses with
scattered necrotic spots and with no cysts (Figs. 3A and C).
Furthermore, these animals exhibited blood stasis in the left
uterine horn (Figs. 3J). The left ovaries of animals in Group C
contained serous fluid-filled cysts (as shown in Fig. 3B; histopath-
ological analyses of the tissue confirmed the presence of
cystadenocarcinomas). Although the ovaries of the rats in the
C+M and C+EtOH+M groups were increased in size (16.463.7
vs. 12.862.5 mm), great differences in the morphological consti-
tution of these ovaries were observed, which were evidenced by
soft and mobile tissues containing no adhesions (Figs. 3 E, F, H
and I). The sham-operated ovaries (*) appeared to be intact with
no macroscopic lesion.
Histological Features of Ovarian Tumors
The majority of ovarian tumors were adenocarcinomas. After
180 days of ovarian tumor induction, the experimental groups
displayed variations in the histotypes and grades of the tumors.
Serous papillary carcinomas were more prevalent in animals from
the C+EtOH (24/80) and C+EtOH+M (22/70) groups than in the
C (10/60) and C+M (6/50) groups. Conversely, clear cell
carcinomas were predominant in animals from the C (5/60) and
C+M (4/50) groups compared to the animals in the C+EtOH (4/
80) and C+EtOH+M (4/70) groups. Sarcomas were more
prevalent in animals from the C (3/60) and C+EtOH (5/80)
groups, and mel therapy was thought to have reduced their
appearance (2/50 in Group C+M and 2/70 in Group
C+EtOH+M). There was a low prevalence of undifferentiated
carcinomas in Groups C (1/60), C+EtOH (1/80) and
C+EtOH+M (1/70), and undifferentiated carcinomas were absent
in Group C+M. Squamous cell carcinomas were present only in
the groups that consumed ethanol, whether they had received mel
(2/80 in Group C+EtOH and 2/70 in Group C+EtOH+M). Only
Groups C (1/60) and C+EtOH (2/80) developed endometrioid
carcinomas and mature cystic teratomas, respectively. Benign
ovarian tumors were identified in Groups C (3/60) and C+M (5/
Table 1. Food consumption (g/day), energy intake (Kcal/day),
and relative water and ethanol consumption (mL/100 g/day)
in all of the experimental groups.
Parameters Vehicle Vehicle+Melatonin
C+EtOH C C+EtOH+M C+M
Food Consumption 15.3160.46 14.8060.65 16.0860.66 14.8960.34
Energy Intake
(food+ethanol)







4.8660.37 0.00 5.2860.12 0.00
Relative Ethanol
Intake (AT)
5.1660.89 0.00 7.8860.62a* 0.00
The values are expressed as the means 6 SD. N = 20/group.
a, b, cp,0.05 versus Groups C+EtOH, C and C+EtOH+M, respectively. Two-way
ANOVA followed by Tukey’s test. PT: Prior to melatonin treatment. AT: After
melatonin treatment.
*p,0.01 differs significantly from relative ethanol intake (PT) compared to
Group C+EtOH+M.
doi:10.1371/journal.pone.0081676.t001
Table 2. Evaluation of estrous cycle (days) and frequency (%) of persistent arrest in the estrous and/or diestrus stage (N = 20/
group).
Groups Duration of Cycles (days) Persistent Estrous/Cycle (%) Persistent Diestrus/Cycle (%)
C+EtOH 9.9560.60 12.67 (0.3;26.67) 47.66 (3.1;65.00)
C 10.5560.45 13.23 (0.9;30.00) 49.80 (4.4;58.97)
C+EtOH+M 7.4560.44* 15.67 (2.5;24.67) 39.00 (8.56;29.33)a
C+M 7.3561.10** 16.67 (3.1;23.00) 34.66 (6.33;46.67)bc
Values are expressed as the means 6 SD and medians (minimum/maximum values).
*p,0.01 and **p,0.05 differs significantly from Groups C+EtOH and C, respectively. Two-way ANOVA followed by Tukey’s test.
a, b, cp,0.05 versus Groups C+EtOH, C and C+EtOH+M, respectively, as analyzed using the Kruskal-Wallis test followed by a post-hoc Dunn’s test.
doi:10.1371/journal.pone.0081676.t002
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50), and were more prevalent in the latter group (Table 4). No
tumors with histological characteristics resembling either granu-
losa cell or germ cell tumors were observed. The most different
types of ovarian carcinomas that were common in the four
experimental groups are illustrated in Figures 4 and 5.
Discussion
The present study is the first to demonstrate an association
between DMBA and 10% (v/v) ethanol intake during ovarian
tumor development, as well as the long-term effects of mel
treatment on the general aspects of the tumors. The evidence
supporting the effects of ethanol on DMBA-induced tumors in a
classic model of UChB rats include the observations that: (a)
ethanol increased the cumulative incidence of ovarian tumors
(post-DMBA injection), (b) the weights and sizes of the tumors
were increased after ethanol consumption, and (c) more tumors
had malignant characteristics in the ethanol consumption group.
Many studies have indicated that ethanol acts as a co-carcinogenic
agent in several diseases [29–31]. Epidemiological studies reported
that a direct correlation between ethanol consumption and the
increased risk for developing ovarian cancer is dependent upon the
amount and exposure time (chronic or more acute exposure), and
that the effects of ethanol on ovarian tumorigenesis seem to be
caused primarily by hormonal disturbances [15,32]. We have
already mentioned the most deleterious effects of chronic ethanol
intake on the ovaries, such as alterations in estrogen- and
progesterone-receptors (ER-alpha, ER-beta, PRA and PRB),
increases in estradiol levels, high ROS production, and changes
in the ovarian structure and ultra-structure [27,33,34]. Further-
more, ethanol and its metabolite, acetaldehyde, are capable of
inducing DNA adduct formation and cytochrome P450-mediated
ROS generation, while also depleting folate levels [29,35,36].
Because these metabolic alterations are linked to the risk of
Table 3. Final body weights (g), body weight gains (%), ovarian sizes (mm), and absolute (g) and relative (g/100 g B.W)
reproductive tissue weights in the four experimental groups.
Parameters Groups
C+EtOH C C+EtOH+M C+M
Final Body Weight 25564.36 25263.59 25863.73 25064.10
Body Weight Gain 2860.4 2660.6 2960.4 2560.8
Left Ovarian Weight* 0.2460.04 0.2260.01 0.1960.02a 0.1760.02b
Relative Weight of the Left Ovary* 0.0960.01 0.0960.01 0.0760.01a 0.0660.01b
Left Ovarian Size* 15.963.7 20.064.2 12.862.5a 16.463.7b
Right Ovarian Weight 0.04860.00 0.05660.00a 0.05960.01a 0.05160.01c
Relative Weight of the Right Ovary 0.0260.00 0.0260.00 0.0360.00 0.0260.00
Oviduct Weight 0.03160.02 0.03360.03 0.02960.01 0.03060.01
Relative Weight of the Oviducts 0.01260.01 0.01360.01 0.01260.03 0.01360.01
Uterine Weight 0.5060.16 0.5360.13 0.4860.15 0.5260.11
Relative Weight of the Uterus 0.1560.04 0.1660.06 0.1860.09 0.1860.08
The values are expressed as the means 6 SD. N = 20/group.
a, b, cp,0.05 versus Groups C+EtOH, C and C+EtOH+M, respectively. (*) indicates that the left ovary was chemically induced with DMBA. Two-way ANOVA followed by
Tukey’s test.
doi:10.1371/journal.pone.0081676.t003
Figure 2. Period of tumor development and plasma melatonin levels during the treatment. Cumulative incidence (%) of ovarian tumors
from 80 to 180 days post-DMBA injection (A). From 120 to 180 days post-DMBA induction, the ovaries of the animals in Group C+EtOH showed a
significant incidence of tumor development. *P,0.05 vs. Group C. (B) Detection of plasma melatonin levels prior to treatment initiation (day 0) and
after 30- and 60- days of treatment. a, bP,0.05 vs. Groups C and C+EtOH, respectively. #P,0.05 vs. 30 days of treatment in the same group.
doi:10.1371/journal.pone.0081676.g002
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Figure 3. Photographs of the most common ovarian tumors 180 days post-DMBA induction. (A and C) The left ovary (arrowhead) of an
animal from the C+EtOH group showing a solid mass with scattered necrosis. (B) The left ovary (arrowhead) of an animal from Group C, displaying a
Ovarian Cancer & Ethanol: Benefits of Melatonin
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developing tumors, ethanol-preferring rats can be an excellent
option for enhancing tumor development in the presence of an
active carcinogen (e.g., DMBA).
In contrast, we report that mel treatment significantly improved
the general aspects of ovarian tumors. Although mel administra-
tion produces alcohol cravings, but not food-seeking behavior, it
can reduce both relative and absolute ovarian tumor weights and
sizes without affecting body weight. We know that OC risk is
strongly linked to an increased number of lifetime ovulations.
Thus, a blockage of incessant ovulation using oral contraceptives,
or even pregnancy, may protect the ovaries from OC [37]. In the
present study, DMBA administration alone, or in combination
larger sized cyst containing serous secretions. High magnification of ovarian neoplasms in the C+EtOH (D), C+M (E), and C+EtOH+M groups (F), and a
sham-operated right ovary (G). The left ovaries (arrowhead) of animals from the C+EtOH+M (H) and C+M (I) groups. (J) Left uterine horn (black arrow),
displaying internal blood stasis. (*) indicates the intact right ovary (which was only treated with the vehicle). Proliferating cancer cells increased the
ovarian masses to diameters .4-fold in size (left ovaries).
doi:10.1371/journal.pone.0081676.g003
Figure 4. Photomicrographs of the three most prevalent intraovarian DMBA-induced ovarian tumors in UChB rats. In Group C, serous
borderline tumors displayed an exophytic papillary architecture (A and B) mixed with extensive micropapillae formation, or tufts back-to-back (C).
The majority of these adenocarcinomas exhibited invasive gland-like neoplastic structures invading the cortex. The C+EtOH (D), C+M (E) and
C+EtOH+M (F) groups presented very complex micropapillary patterns, composed of columnar atypical cells, with no stromal invasion. Clear cell
carcinomas (asterisk) with solid growths surrounding the stromal tissues were observed in Groups C (G), C+EtOH (H), C+M (I) and C+EtOH+M (J).
Sarcoma cells (asterisk) were arranged in bundles and streams with spindle shapes and occupied extramedullary sites in Groups C (K), C+EtOH (L),
C+M (M) and C+EtOH+M (N). Sham-operated right ovaries with developing and mature follicles and new corpora lutea in Groups C (O), C+EtOH (P),
C+M (Q) and C+EtOH+M (R). Original low magnification, bar = 200 mm; H&E stain.
doi:10.1371/journal.pone.0081676.g004
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Figure 5. Histologic subtypes of ovarian tumors in the four experimental groups. In Group C: A) Serous carcinoma characterized by
papillae formation with cellular budding (arrows), bar = 20 mm. B) Clear cell carcinoma composed of numerous vacuolated cells, bar = 20 mm. C)
Ovarian carcinoma in situ. The epithelium is composed of stratified cells with loss of nuclear polarity and nuclear pleomorphism with chromatin
clumping (arrowhead), bar = 20 mm. D) Sarcoma composed of non-epithelial malignant cells, bar = 20 mm. In Group C+M: E) Serous carcinoma with a
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with EtOH, induced a late prolonged estrous cycle in rats when
the ovaries already displayed evidence of tissue lesions. However,
no anovulatory cycles were observed. Conversely, mel restored
estrous cycle duration to near normal, and also reduced the
diestrus stage. The low water intake observed in UChB rats was
due to increases in the ethanol/ethanol+water ratios, and not to
mel treatment [27]. In support of these data, mel is involved in the
acquisition of ethanol preference rather than the maintenance of
ethanol intake, thereby providing evidence that melatonin
antagonists may reduce the reinforcement of ethanol consumption
[38]. Corroborating the ovarian tumor reduction data, Srinivasan
et al. [39] reported that melatonin is effective in suppressing
neoplastic growth in a variety of reproductive tract tumors,
including ovarian tumors. The main mechanism seems to be due
to the immunoenhancing properties of melatonin in stimulating T-
helper cell responses by releasing interleukin-2 and -10 and
interferon-c. In addition, melatonin prevents free radical damage
in normal and tumor tissues, and induces the apoptotic
mitochondrial pathway by reducing Bcl2 expression and cas-
pase-3 activity [40,41]. There may also be an anti-proliferative
effect of melatonin in hormone-dependent tumors in UChB rats,
such as that evidenced in mice [42]. Under normal conditions,
melatonin at doses of 200 mg/100 g of BW/day induced longer
estrous periods and reductions in ovarian weight [43]. Our
previous reports suggested that long-term mel treatment satisfac-
torily reduces ovarian lipoperoxidation and plasma estradiol levels,
while enhancing tissue antioxidant defenses [27,28]. Moreover,
mel treatment was also associated with lower ovarian weights and
estrous cycle synchronization [44].
In the present study, we determined the ovarian tumor subtype
based on histological observations. Spontaneous development of
epithelial cancers is rarer in rodent ovaries [45] than in the ovaries
of human beings. One plausible explanation for the low incidence
is the fact that the rat ovaries are surrounded by a membranous
pouch, which provides natural protection against the local effects
of carcinogens [46]. To date, most of the studies of DMBA-
induced tumors in rodent species (rat or mice) have generated
reproducible ovarian neoplasms using various simulation methods
and routes of carcinogen administration [11,26,47,48], including
gavage, coated suture or local instillation, dosage, time of drug
delivery, and appropriate time for tumor development and
growth. Interestingly, 120 days post-DMBA induction, the
incidence of ovarian tumors was significantly increased after
ethanol consumption (60% in the controls vs. 74% in the EtOH-
treated group), of which 48% were adenocarcinomas of surface
epithelial origin. Therefore, the development of neoplasms in
DMBA-treated rats that had undergone ovarian failure (constant
ethanol exposure) demonstrates an elevated susceptibility to
develop ovarian tumors. However, the exact mechanism(s)
involved in this ovarian sensitivity require further investigation.
Although ethanol has the ability to act systematically on the whole
ovary, all of the ovarian tumors were originated from the surface
epithelium or cysts. It is believed that tumor origin may be related
more to disruptions of the OSE than to perturbations of follicular
or stromal tissues. Some of the DMBA-induced lesions, especially
those related to the surface epithelium, were similar to the isolated
papillae or diffuse papillomatosis found in human OC. Addition-
ally, other OSE-derived structures that are commonly described in
humans (i.e., simple microcysts or serous cysts) were eventually
observed in the rat ovaries. In the present study, the development
of the putative precursor lesions associated with DMBA exhibited
degrees of differentiation and progression (i.e., cellular atypia and
dysplasia) varying from low- to high-grade malignant potential.
Briefly, clear cell carcinomas and sarcomas displayed similar
features to those that occur in women. Several studies have shown
a stronger relationship between DMBA-induced OC and human
OC, both at the morphological and molecular levels [48–50].
Although DMBA is not a known environmental carcinogen that is
linked to OC, it may share mutagenic mechanisms with other
polycyclic aromatic compounds that are present at high concen-
trations in air pollutants or in tobacco, both of which have been
implicated to play roles in human cancer development.
Further strengthening our findings, plasma mel concentrations
were significantly elevated in the animals from both the C+M and
C+EtOH+M groups, which ensured that an effective long-term
therapy schedule had been followed. Although ethanol intake had
been described to inhibit plasma mel [51], it was not sufficient to
alter the continuous availability of mel in the early morning during
the treatment period. Additionally, the nocturnal peaks of mel
appeared to exacerbate both locomotor activity and EtOH-seeking
behavior, while no apparent influence on the daytime behavior of
the animals was observed. A notable activity rhythm after the
administration of exogenous mel is typically found in nocturnal
species (e.g., rodents) [52].
pattern of papillae, bar = 50 mm. F) Serous papillary cystadenoma (borderline tumor) showing a higher complexity of cellular stratification,
bar = 20 mm. G) Pattern of clear cell carcinoma with hobnail cells, bar = 20 mm. H) Sarcoma, bar = 20 mm. In Group C+EtOH: I) Serous carcinoma
showing a section of a papillae (arrow), bar = 20 mm. J) Squamous carcinoma composed of squamous epithelial cells (asterisk), bar = 50 mm. K)
Mature cystic teratoma with malignant content were scattered in the ovarian stroma (white arrows), bar = 50 mm. L) Clear cell carcinoma,
bar = 20 mm. M) Sarcoma, bar = 20 mm. In Group C+EtOH+M, serous carcinoma showing a cross-section of a papillae (N), bar = 20 mm. O) Squamous
carcinoma, bar = 50 mm. P) Ovarian carcinoma with the presence of specifically undifferentiated cells (asterisk). The stroma displayed a marked
infiltration of inflammatory cells (arrow), bar = 20 mm. Q) Sarcoma, bar = 20 mm; H&E stain.
doi:10.1371/journal.pone.0081676.g005
Table 4. Prevalence (%) of the different ovarian tumor
subtypes, observed 180 days after DMBA injection in the four
experimental groups.
Histologic Types Groups
C C+M C+EtOH C+EtOH+M
Serous Papillary 16.6% 12.05% 30.00% 31.33%
Clear Cell
Carcinoma
8.50% 7.63% 5.11% 5.95%
Sarcoma 5.00% 3.84% 6.25% 2.85%
Undifferentiated
Carcinoma
1.65% – 1.25% 1.43%
Squamous Cell
Carcinoma
– – 2.50% 2.86%
Endometrioid
Carcinoma
1.66% – – –
Mature Cystic
Teratoma
– – 2.50% –
Benign Ovarian
Tumor
5.02% 10.07% – –
N = 20/group.
doi:10.1371/journal.pone.0081676.t004
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In regard to advanced ovarian tumors, melatonin alone reduced
the incidence of serous papillary carcinomas, while the combina-
tion of DMBA with ethanol increased their appearance, regardless
of mel treatment. This may be attributed to the effects of ethanol
more than to the effects of DMBA itself. Conversely, a low
incidence of clear cell carcinomas was observed after DMBA plus
ethanol intake, and mel did not seem to affect this tumor subtype.
In both ethanol-consuming and control animals, a low incidence
of sarcomas was observed following melatonin treatment. Undif-
ferentiated carcinomas had a very low incidence, and mel
treatment alone suppressed its development. Intriguingly, only
the combination of DMBA and ethanol intake led to the
development of squamous cell carcinomas, and mel did not affect
these tumors. There was also a low incidence of endometrioid
carcinomas and mature cystic teratomas in the DMBA- and
DMBA+ethanol treated groups, respectively. A high incidence of
benign ovarian tumors was observed in DMBA-treated rats, and
mel treatment further increased the incidence. In this group, mel
may have exerted a beneficial effect, as evidenced by the reduced
incidence of malignant ovarian tumors.
Notably, no inhibitory effects of melatonin (1 and 100 nM) on
the growth of ovarian cancer cells in culture medium enriched
with 1 nM 17b-estradiol were observed in in vitro studies [53].
Taking into account the fact that various experimental conditions
were modified, such as differing melatonin incubation times (from
48 to 144 h) with stimulatory repetition every 24 h, or the use of
different culture media, the effects of melatonin may be
undetectable due to these variations. In addition, in vitro studies
using different doses of mel (50, 100 and 200 nM) are being
conducted on primary OC cultures originating from UChB rats
(preliminary data not shown).
Altering the progression of DMBA-initiated cells to the
formation of a tumor is an incessant paradigm in the chemopre-
vention area. Studies conducted by our research group examining
chemoprevention and chemoresistance to drugs using this rat
model are currently underway to assess the effectiveness of
melatonin in stimulating immune function and inhibiting ovarian
tumorigenesis.
In summary, chronic ethanol consumption enhanced the
incidence of ovarian carcinomas in the presence of intraovarian
DMBA. Furthermore, the association of DMBA with ethanol
intake caused an increase in ovarian tumor mass with a high
prevalence of malignant histologic subtypes. Although mel
treatment promoted significant increases in ethanol consumption,
it was able to effectively reduce ovarian mass. In addition to these
benefits, mel also reduced the incidence of ovarian adenocarcino-
mas in ethanol-deprived rats. These data represent an important
benchmark for understanding ovarian cancer development in a
model of ethanol-preferring rats, and also suggest that melatonin
may potentially be used as adjuvant therapy.
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